{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:55:53Z","timestamp":1761630953924,"version":"3.41.2"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Anti-TNF\u03b1 agents have been a staple of Crohn\u2019s disease treatment for 20 years, but they have weaknesses. New treatments have more recently become available. The aim of this paper is to examine the Crohn\u2019s disease patient population for whom anti-TNF treatments are not preferred and where new mechanisms of action should be considered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A representative sample of 100 Italian physicians with documented expertise with biological treatment of moderate-to-severe Crohn\u2019s disease were interviewed. A literature review on Crohn\u2019s disease treatment was also conducted to identify patient populations for whom anti-TNFs are unsuitable.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>On the basis of the interviewed physicians, about 9% of moderate-to-severe Crohn\u2019s disease patients were noneligible to anti-TNF\u03b1 due to contraindication or possible risk of intolerance, while 11% had discontinued anti-TNF\u03b1 treatment due to complications or intolerance\/hypersensitivity. Patients with severe heart disease and at high risk of infections were more frequently considered unsuitable. The proportion of patients considered unsuitable among elderly patients and in those with recurrent infections, cancer, and other comorbidities ranged between 40 and 60%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We provided additional quantitative and qualitative information to help identify patients who are less suitable to anti-TNF agents, who could benefit from newer biologic agents with different mechanisms of action.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/meg.0000000000002183","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T16:13:58Z","timestamp":1620576838000},"page":"1082-1090","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Who are the patients with Crohn\u2019s disease unsuitable to receive an anti-TNF\u03b1 therapy? Results from a survey of Italian physicians and literature review"],"prefix":"10.1097","volume":"33","author":[{"given":"Flavio","family":"Caprioli","sequence":"first","affiliation":[{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano and Gastroenterology and Endoscopy Unit, Fondazione IRCCS C\u00e0 Granda, Ospedale Policlinico di Milano, Milan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Daperno","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Ospedale Ordine Mauriziano di Torino, Turin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Bravat\u00e0","sequence":"additional","affiliation":[{"name":"Janssen-Cilag SpA, Cologno Monzese"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Brigido","sequence":"additional","affiliation":[{"name":"Janssen-Cilag SpA, Cologno Monzese"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Frigerio","sequence":"additional","affiliation":[{"name":"Janssen-Cilag SpA, Cologno Monzese"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ottavio","family":"Secchi","sequence":"additional","affiliation":[{"name":"Janssen-Cilag SpA, Cologno Monzese"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rispo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University of Naples \u2018Federico II,\u2019 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"R1-20250801","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ibd.21417","article-title":"Long-term complications, extraintestinal manifestations, and mortality in adult Crohn\u2019s disease in population-based cohorts.","volume":"17","author":"Peyrin-Biroulet","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R2-20250801","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease.","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"R3-20250801","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/gut.2003.031476","article-title":"Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn\u2019s disease patients: the Florence IBD study 1978-2001.","volume":"53","author":"Masala","year":"2004","journal-title":"Gut"},{"key":"R4-20250801","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrgastro.2013.31","article-title":"First-line therapy in adult Crohn\u2019s disease: who should receive anti-TNF agents?.","volume":"10","author":"Peyrin-Biroulet","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R5-20250801","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/gut.2010.227884","article-title":"Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn\u2019s disease.","volume":"60","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gut"},{"key":"R6-20250801","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial.","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"R7-20250801","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apt.13475","article-title":"Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn\u2019s disease.","volume":"43","author":"Shah","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R8-20250801","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease.","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"R9-20250801","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease.","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"R10-20250801","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/apt.15685","article-title":"Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn\u2019s disease.","volume":"51","author":"Ungaro","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R11-20250801","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/ibd\/izaa031","article-title":"Early vs late use of anti-TNFa therapy in adult patients with Crohn disease: a systematic review and meta-analysis.","volume":"26","author":"Hamdeh","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"R12-20250801","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis.","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R13-20250801","doi-asserted-by":"crossref","first-page":"h2809","DOI":"10.1136\/bmj.h2809","article-title":"Association between tumour necrosis factor-\u03b1 inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study.","volume":"350","author":"Nyboe Andersen","year":"2015","journal-title":"BMJ"},{"key":"R14-20250801","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ibd.23026","article-title":"Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease.","volume":"19","author":"Desai","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R15-20250801","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/apt.15371","article-title":"Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn\u2019s disease: results from the ENEIDA registry.","volume":"50","author":"Iborra","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R16-20250801","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/MIB.0000000000001074","article-title":"Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe Crohn\u2019s disease: real-world experience from a multicenter cohort study.","volume":"23","author":"Ma","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R17-20250801","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/14712598.2020.1707800","article-title":"Effectiveness and safety of Ustekinumab for the treatment of Crohn\u2019s disease in real-life experiences: a meta-analysis of observational studies.","volume":"20","author":"Macaluso","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"R18-20250801","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/ecco-jcc\/jjz080","article-title":"Long-term clinical effectiveness of ustekinumab in patients with Crohn\u2019s disease who failed biologic therapies: a national cohort study.","volume":"13","author":"Liefferinckx","year":"2019","journal-title":"J Crohns Colitis"},{"key":"R19-20250801","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ygh2.331","article-title":"Barriers to anti-TNFalpha prescription among Italian physicians managing inflammatory bowel disease.","volume":"1","author":"Bezzio","year":"2019","journal-title":"GastroHep"},{"key":"R20-20250801","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1007\/s10620-010-1530-9","article-title":"Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn\u2019s disease: a US national practice survey comparing experts and non-experts.","volume":"56","author":"Swaminath","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R21-20250801","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.crohns.2011.12.013","article-title":"Adherence of gastroenterologists to European Crohn\u2019s and Colitis Organisation consensus on Crohn\u2019s disease: a real-life survey in Spain.","volume":"6","author":"Hinojosa","year":"2012","journal-title":"J Crohns Colitis"},{"key":"R22-20250801","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.17554\/j.issn.2224-3992.2014.03.461","article-title":"Current practice of anti-TNF-\u03b1 treatment in inflammatory bowel disease: results from a National Survey in Sweden.","volume":"3","author":"Hindorf","year":"2014","journal-title":"J Gastroenterol Hepatol Res"},{"key":"R23-20250801","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/apt.12616","article-title":"Systematic review with meta-analysis: inflammatory bowel disease in the elderly.","volume":"39","author":"Gisbert","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R24-20250801","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40266-020-00744-3","article-title":"Persistence on anti-tumour necrosis factor therapy in older patients with inflammatory bowel disease compared with younger patients: data from the Sicilian network for inflammatory bowel diseases (SN-IBD).","volume":"37","author":"Porcari","year":"2020","journal-title":"Drugs Aging"},{"key":"R25-20250801","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","article-title":"Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.","volume":"9","author":"Cottone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R26-20250801","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/ecco-jcc\/jjaa012","article-title":"Increased discontinuation rates of anti-TNF therapy in elderly inflammatory bowel disease patients.","volume":"14","author":"de Jong","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R27-20250801","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11894-019-0669-6","article-title":"Managing risks with biologics.","volume":"21","author":"Click","year":"2019","journal-title":"Curr Gastroenterol Rep"},{"key":"R28-20250801","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ecco-jcc\/jjaa025","article-title":"Anti-TNF agents in elderly IBD patients: cause for concern?.","volume":"14","author":"L\u00f6wenberg","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R29-20250801","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/gut.2003.018515","article-title":"Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.","volume":"53","author":"Ljung","year":"2004","journal-title":"Gut"},{"key":"R30-20250801","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jgh.12958","article-title":"Asia-Pacific consensus statements on Crohn\u2019s disease. Part 2: management.","volume":"31","author":"Ooi","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"R31-20250801","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"R32-20250801","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejim.2012.12.015","article-title":"Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases.","volume":"24","author":"Sinagra","year":"2013","journal-title":"Eur J Intern Med"},{"key":"R33-20250801","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults.","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"R34-20250801","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/rheumatology\/kem212","article-title":"Heart failure among younger rheumatoid arthritis and Crohn\u2019s patients exposed to TNF-alpha antagonists.","volume":"46","author":"Curtis","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R35-20250801","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ahj.2008.02.025","article-title":"Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis.","volume":"156","author":"Setoguchi","year":"2008","journal-title":"Am Heart J"},{"key":"R36-20250801","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI38482","article-title":"Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans.","volume":"119","author":"Bruns","year":"2009","journal-title":"J Clin Invest"},{"key":"R37-20250801","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/ajg.2011.211","article-title":"The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn\u2019s and Colitis Organisation: safety.","volume":"106","author":"Van Assche","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 2","key":"R38-20250801","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents).","volume":"24","author":"Baddley","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"R39-20250801","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jaad.2015.11.043","article-title":"Use of tumor necrosis factor (TNF) inhibitors in patients with HIV\/AIDS.","volume":"74","author":"Gallitano","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R40-20250801","doi-asserted-by":"crossref","first-page":"487","DOI":"10.12659\/MSM.890331","article-title":"A guide to prepare patients with inflammatory bowel diseases for anti-TNF-\u03b1 therapy.","volume":"20","author":"Chebli","year":"2014","journal-title":"Med Sci Monit"},{"key":"R41-20250801","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management.","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R42-20250801","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/ibd\/izaa084","article-title":"Challenges in the care of IBD patients during the CoViD-19 pandemic: report from a \u201cRed Zone\u201d area in Northern Italy.","volume":"26","author":"Occhipinti","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"R43-20250801","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/j.gastro.2020.04.002","article-title":"Management of patients with Crohn\u2019s disease and ulcerative colitis during the coronavirus disease-2019 pandemic: results of an international meeting.","volume":"159","author":"Rubin","year":"2020","journal-title":"Gastroenterology"},{"key":"R44-20250801","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: a meta-analysis.","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R45-20250801","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cgh.2013.04.033","article-title":"Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis.","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R46-20250801","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"R47-20250801","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease.","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"JAMA"},{"key":"R48-20250801","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/ibd\/izx072","article-title":"Infliximab for Crohn\u2019s disease: more than 13 years of real-world experience.","volume":"24","author":"Lichtenstein","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R49-20250801","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S2468-1253(19)30362-0","article-title":"Anti-tumour necrosis factor-\u03b1 therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study.","volume":"5","author":"Waljee","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R50-20250801","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ajg.2010.392","article-title":"The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn\u2019s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?.","volume":"106","author":"D\u2019Haens","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R51-20250801","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1530\/REP-13-0232","article-title":"Influence of infection during pregnancy on fetal development.","volume":"146","author":"Adams Waldorf","year":"2013","journal-title":"Reproduction"},{"key":"R52-20250801","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1080\/00365521.2016.1208269","article-title":"Preterm birth in women with inflammatory bowel disease - the association with disease activity and drug treatment.","volume":"51","author":"Br\u00f6ms","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"R53-20250801","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/pds.4930","article-title":"Anti-TNF treatment during pregnancy and birth outcomes: a population-based study from Denmark, Finland, and Sweden.","volume":"29","author":"Br\u00f6ms","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R54-20250801","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","article-title":"Continuous anti-TNF\u03b1 use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective Cohort on the French National Health Insurance Database (EVASION).","volume":"113","author":"Luu","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"R55-20250801","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2015.08.039","article-title":"Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy.","volume":"14","author":"Br\u00f6ms","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R56-20250801","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.dld.2017.01.141","article-title":"Safety of treatments for inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).","volume":"49","author":"Biancone","year":"2017","journal-title":"Dig Liver Dis"},{"key":"R57-20250801","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ecco-jcc\/jju006","article-title":"The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease.","volume":"9","author":"van der Woude","year":"2015","journal-title":"J Crohns Colitis"},{"key":"R58-20250801","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","article-title":"Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease.","volume":"160","author":"Mahadevan","year":"2021","journal-title":"Gastroenterology"},{"key":"R59-20250801","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","article-title":"The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy.","volume":"150","author":"Nguyen","year":"2016","journal-title":"Gastroenterology"},{"key":"R60-20250801","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00535-018-1439-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease.","volume":"53","author":"Matsuoka","year":"2018","journal-title":"J Gastroenterol"},{"key":"R61-20250801","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.gastro.2018.05.040","article-title":"Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development.","volume":"155","author":"Matro","year":"2018","journal-title":"Gastroenterology"},{"key":"R62-20250801","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.gastro.2007.05.006","article-title":"American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.","volume":"133","author":"Clark","year":"2007","journal-title":"Gastroenterology"},{"key":"R63-20250801","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dld.2010.07.010","article-title":"The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.","volume":"43","author":"Orlando","year":"2011","journal-title":"Dig Liver Dis"},{"key":"R64-20250801","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaa104","article-title":"Clinical features and genetic risk of demyelination following anti-TNF treatment.","author":"Lin","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R65-20250801","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-\u03b1 blockers.","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R66-20250801","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2036.2011.04682.x","article-title":"Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.","volume":"34","author":"Steenholdt","year":"2011","journal-title":"Aliment Pharmacol Ther"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T17:10:04Z","timestamp":1754068204000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000002183","relation":{},"ISSN":["0954-691X"],"issn-type":[{"type":"print","value":"0954-691X"}],"subject":[],"published":{"date-parts":[[2021,5,3]]}}}